Vor Biopharma (NASDAQ:VOR) Shares Down 6.5% on Disappointing Earnings

Vor Biopharma Inc. (NASDAQ:VOR)’s stock price traded down 6.5% on Wednesday following a dissappointing earnings announcement. The company traded as low as $22.13 and last traded at $22.0450. 173,608 shares were traded during trading, a decline of 84% from the average session volume of 1,065,662 shares. The stock had previously closed at $23.59.

The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11).

Wall Street Analysts Forecast Growth

VOR has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and set a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th. Wedbush increased their price target on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Weiss Ratings upgraded Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new position in shares of Vor Biopharma in the fourth quarter worth $36,000. Squarepoint Ops LLC bought a new stake in shares of Vor Biopharma during the third quarter valued at about $230,000. Bank of America Corp DE lifted its holdings in Vor Biopharma by 679.3% in the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock worth $232,000 after purchasing an additional 4,144 shares during the period. BNP Paribas Financial Markets lifted its holdings in Vor Biopharma by 497.3% in the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after purchasing an additional 5,058 shares during the period. Finally, Bridgeway Capital Management LLC bought a new position in Vor Biopharma in the 3rd quarter valued at about $304,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Price Performance

The stock’s 50-day moving average is $18.00 and its 200-day moving average is $15.88.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).